middle.news
Garvan Institute Secures $3M Grant to Test Syntara’s Drug in Pancreatic Cancer Trial
10:32am on Wednesday 21st of January, 2026 AEDT
•
Healthcare
Read Story
Garvan Institute Secures $3M Grant to Test Syntara’s Drug in Pancreatic Cancer Trial
10:32am on Wednesday 21st of January, 2026 AEDT
Key Points
Garvan Institute awarded $3 million MRFF grant for pancreatic cancer clinical trials
One study to test Syntara’s amsulostat (SNT-5505) with standard chemotherapy
Syntara provides drug and expertise without cash funding
Trial recruitment expected mid-2026 at NSW cancer centres
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE